Overview

Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)

Status:
Recruiting

Trial end date:
2024-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to study the effect of giving nivolumab with CCR2/5-inhibitor or anti-IL-8 before surgery, and after surgery, with the goal of determining if this medicine results in: 1. A significant immune response against their tumor (which the study team will see in the tumor that is taken out at the time of surgery) 2. Improvement in long term survival rates

Phase:

Phase 2

Details

Lead Sponsor:

Icahn School of Medicine at Mount Sinai

Collaborator:

Bristol-Myers Squibb

Treatments:

Nivolumab